- Home
- VTGN vs CTXR Comparison
VTGN vs CTXR Comparison
Compare VTGN & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | CTXR |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 18.9M |
| IPO Year | 2014 | 2010 |
Fundamental Metrics
Financial Performance| Metric | VTGN | CTXR |
|---|---|---|
| Price | $0.56 | $0.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $0.90 | ★ $6.00 |
| AVG Volume (30 Days) | 422.3K | ★ 488.4K |
| Earning Date | 02-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.63 |
| 52 Week High | $5.14 | $2.38 |
Technical Indicators
Market Signals| Indicator | VTGN | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 49.95 |
| Support Level | $0.50 | $0.68 |
| Resistance Level | $0.66 | $0.98 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 34.57 | 50.82 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.